Zobrazeno 1 - 10
of 86
pro vyhledávání: '"M. Paraire"'
Autor:
Nicholas H. G. Holford, Christian Laveille, M. Francillard, M. Paraire, Nicolas Frey, Roeline Jochemsen
Publikováno v:
British Journal of Clinical Pharmacology. 55:147-157
Aims To study the relationship between the pharmacokinetics (PK) of gliclazide and its long-term pharmacodynamic (PD) effect in a large population of Type 2 diabetic patients and to identify factors predicting intersubject variability. Methods A PKPD
Publikováno v:
Biopharmaceutics & Drug Disposition. 23:151-157
A new modified release (MR) formulation containing 30 mg of gliclazide was developed to obtain a better predictable release of the active principle and to allow once-daily dosing regimen. An absolute bioavailability study was carried out to character
Publikováno v:
British journal of clinical pharmacology. 55(2)
To study the relationship between the pharmacokinetics (PK) of gliclazide and its long-term pharmacodynamic (PD) effect in a large population of Type 2 diabetic patients and to identify factors predicting intersubject variability.A PKPD database of 6
Publikováno v:
Bulletin du cancer. 81(10)
Publikováno v:
European Journal of Cancer. 29:S113
Autor:
B. Mazier, M. Berlion, C. Lucas, M. Paraire, J. Berille, B. Giroux, B. Gérard, M. Sarkany, J.P. Bizzari
Publikováno v:
Drugs of the Future. 18:711
Autor:
EL MOUNCHARIH, ABDELKARIM1 a.elmouncharih@gmail.com, TAKASSA, RABI1, FARKAD, OMAR1, TCHENKA, ABDELAZIZ1, IBNOUELGHAZI, EL ALAMI1, ABOUELAOUALIM, DRISS1
Publikováno v:
Optica Applicata. 2023, Vol. 53 Issue 3, p407-418. 12p.
Publikováno v:
Anticancer research. 9(6)
Fotemustine is a new chloroethylnitrosourea which has recently entered a Phase II clinical trial. Using standard cytotoxicity analyses, Fotemustine was shown to be preferentially active in two Mer- cell lines, human colon BE and human lung A427. Comp
Autor:
R, Bourbouze, J C, Gluckman, P, Frantz, M, Paraire, F C, Baumann, J, Luciani, F, Percheron, M, Legrain
Publikováno v:
Clinica chimica acta; international journal of clinical chemistry. 149(2-3)
Monitoring of variations in N-acetyl-beta-D-glucosaminidase (NAG) urinary activity, following renal transplantation, has been proposed for the early diagnosis of rejection episodes. In this study, the measurement of urinary NAG-B activity was conduct